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Background: Antibiotic surveillance is mandatory to optimise antibiotic therapy. Our objectives were to evaluate
antibiotic use in our pediatric intensive care unit (PICU) and to implement a simple achievable intervention aimed
at improving antibiotic therapy.
Method: Prospective, 3 months surveillance of antibiotic use on PICU (phase I) and evaluation according to the
CDC 12-step campaign with development of an attainable intervention. 3 months surveillance (phase II) after
implementation of intervention with comparison of antibiotic use.
Results: Appropriate antibiotic use for culture-negative infection-like symptoms and targeted therapy for proven
infections were the main areas for potential improvement. The intervention was a mandatory checklist requiring
indication and recording likelihood of infection at start of antibiotic therapy and a review of the continuing need
for therapy at 48 h and 5 days, reasons for continuation and possible target pathogen. The percentage of
appropriate empiric antibiotic therapy courses for culture-negative infection-like symptoms increased from 18%
(10/53) to 74% (42/57; p<0.0001), duration of therapy <3 days increased from 18% (10/53) to 35% (20/57; p=0.05)
and correct targeting of pathogen increased from 58% (7/12) to 83% (20/24; p=0.21).
Conclusions: Antibiotic surveillance using the CDC 12-step campaign can help to evaluate institutional antibiotic
therapy. Development of an attainable intervention using a checklist can show improved antibiotic use with
minimal expense.
Keywords: Antibiotic surveillance, Paediatric intensive care unit, CDC 12-Step Campaign, Checklist, antimicrobial
stewardship programBackground
Antibiotic surveillance is mandatory to optimise anti-
biotic therapy and to prevent antimicrobial resistance
[1-3]. Guidelines for developing an institutional program
to enhance antimicrobial stewardship are published and
contain several interventions with good impact but re-
quire a high level of organisational change, resources
and acceptance [4]. Only a small number of studies have
focused on antibiotic surveillance on hospitalised new-
borns, infants and children [5-8]. In a recent published
survey, Hersh et al. pointed out that lack of resources,* Correspondence: stockermartin@mail.com
1Paediatric and Neonatal Intensive Care Unit, Children’s Hospital Lucerne,
Lucerne, Switzerland
Full list of author information is available at the end of the article
© 2012 Stocker et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orincluding funding, time, and personnel were the major
barriers to implementing an antimicrobial stewardship
program in paediatrics [9].
The Center for Disease Control and Prevention (CDC)
12-step program to prevent antimicrobial resistance was
launched in 2000 to educate clinicians about antimicrobial
resistance and provide strategies to improve clinical prac-
tice [10]. Patel and colleagues showed in a recent publica-
tion the possibility of using the CDC 12-Step Campaign to
assess antibiotic prescribing and adherence to guidelines
on a Neonatal Intensive Care Unit (NICU) [8].
In a recently published concise review, Newland and
Hersh concluded that prospective audit with feedback
was the most favourable and efficient strategy for anti-
microbial stewardship programs in paediatrics [11]. TheyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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declared the most important challenge was to develop
strategies to facilitate greater implementation of anti-
microbial stewardship programs at low cost and low
resource requirement. In line with these conditions
our aim was to conduct an antibiotic surveillance
audit on our Paediatric Intensive Care Unit (PICU)
with a simple achievable strategy at low cost and low
resource requirement.
Method
We performed a prospective, single-centre interven-
tional audit of antibiotic use on our PICU. Antibiotic
therapy was assessed looking for adherence best practice
recommendations of the CDC 12-step campaign. Basic
data collection was carried out for 3 months (phase I).
Interventions were then planned based on areas for po-
tential improvement, that were simple and attainable,
required minimal personnel resources and were low in
cost (no funding available). Data collection was repeated
after the intervention based on the power calculation
(phase II). The audit was supervised by the depart-
ments of Paediatrics, Pharmacy and Microbiology at
the Royal Brompton and Harefield NHS Foundation
Trust. The results of phases I and II were reviewed
as part of the clinical governance program. This audit
with an implemented intervention that is part of
standard care on our PICU without a change in policy
didn't required ethical approval.
Site and subjects
This audit was conducted on the PICU at the Royal
Brompton and Harefield NHS Foundation Trust in
London, UK. Our unit is a specialised, tertiary unit for
paediatric cardio-respiratory care with approximately
700 admissions per year. Newborns and children up to
16 years of age with a broad spectrum of cardiac malfor-
mations, cardiac diseases, rhythm disturbances, post-
operative cardiorespiratory care and respiratory problems
are treated in our facility. All admissions between 1st April
2010 and 31st June 2010 (91 days) were included in
phase I, and then between 10th November 2010 and
28th February 2011 (110 days) in phase II.
Staff of the unit includes physicians (intensivists, cardi-
ologists, respiratory physicians, anaesthesists, cardiothor-
acic and general paediatric surgeons) working as
consultants, fellows and senior house officers; nursing
staff working usually in 1:1 care (1 nurse / 1 patient),
partially 1:2 if patients were stable and not invasively
ventilated; pharmacists and allied health professionals.
The group of physicians prescribing antibiotics remained
unchanged in regard of number and level of expertise
during both study periods: 5 consultant intensivists, 9
fellow intensivists and 9 senior house officers (Paediatrics).Infection control is part of our standard practises on our
unit and two infection-focused care bundles are actively
practised with prospective data collection: i) care bundle
for prophylaxis of catheter-related infections, ii) care bun-
dle for prophylaxis of ventilator-associated pneumonia.
Both care bundles remained unchanged and there were
no other stewardship interventions in place during the
study phase.
Data collection
Data collection in both phases was carried out using the
electronic prescribing system for medication (ICIP),
the electronic microbiology data system (EPR), the
electronic system for nursing reports and all available
medical reports. With the electronic medication and
microbiology data system we were able to assess all
doses of antibiotic therapy administered to patients
on PICU, and results of all microbiologically tested
samples (blood, cerebrospinal fluid, ascites, urine, tra-
cheal aspirates). Indications for antibiotic therapy
were obtained from medical and nursing reports in
phase I, and additionally from the study intervention
form during phase II.
Definitions and assessment of antibiotic use
The design of our study was an antibiotic surveillance
audit, based on the CDC 12-step recommendations fo-
cused at the 2 strategies “Diagnose and treat infection
effectively” (steps 3–5) and “Use antimicrobials wisely”
(steps 6–10). The unit of antibiotic analysis was an anti-
biotic course, defined as one or more antibiotics given
concurrently for one or more days. The possible reasons
for therapy were categorised as 1) prophylaxis (post-sur-
gery), 2) empiric therapy (clinical signs of possible infec-
tion with negative cultures) or 3) therapy for proven
infection (clinical signs of infection with positive cul-
tures from blood, cerebrospinal fluid, ascites, urine or
tracheal aspirates). Appropriateness of antibiotic use was
compared using institutional antimicrobial guidelines for
prophylaxis and empiric therapy for suspected infec-
tions. Appropriate duration of empiric therapy for cul-
ture negative infection-like symptoms was defined as
less than 3 days unless there were clear and reasonable
documented reasons for continuing antibiotic therapy.
A checklist as a simple achievable intervention
After defining 2 main areas for potential improvement
in phase I, we created a checklist as a simple achievable
intervention (Figure 1). The checklist was introduced to
the multidisciplinary team of the PICU without further
education regarding antibiotic prescribing policy. The
intervention was a mandatory form (one page per anti-
biotic course) for all children receiving antibiotics
(except prophylaxis). The checklist requested indication
Figure 1 Checklist for antibiotic stewardship.
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therapy, review of therapy at 48 hours and 5 days,
recording reasons for continuing therapy and targeting
therapy towards the pathogen if cultures were positive.
The likelihood of infection estimated by the treating
physician was scaled. This initial impression was
intended to guide subsequent in deciding whether anti-
biotic therapy could be stopped after 48 hours. The
forms were reviewed and updated twice daily by the
treating physician (fellow or consultant intensivist).There was no strict monitor system regarding compliance
and adherence to the intervention. Pharmacists
working on the ward controlled at random use of the
checklist and approached physicians not following
the instructions.
Statistics
A power calculation was done based on the aim of our
primary intervention, which was to reduce inappropriate
duration of empiric antibiotic therapy with culture







Admissions 174 185 0.48
Hospitalisation days 952 1186 0.84
Hospitalisation days / admissiona 5.47 (1/3/41) 6.41 (1/3/71) 0.24
Fatal casualities 0 3 0.25
Infection-related fatal casualities 0 0 1
Sex (% male) 58% 60.5% 0.23
Age at admissionb 6 mt 7 mt 0.48
Stocker et al. BMC Pediatrics 2012, 12:196 Page 4 of 6
http://www.biomedcentral.com/1471-2431/12/196negative results. In phase I, 18% (10/53) of patients on
empiric therapy received it for an appropriate duration.
We hypothesised, that it was possible to increase this to
36% (duplication) with the implemented intervention.
With the definition of alpha=0.05 and a power of 80%,
42 courses of empiric therapy would be required to
demonstrate a significant result. Calculating a possible
compliance of 80% to the intervention our aim was to
observe 52 courses of empiric antibiotic therapy during
phase II. A Chi-squared test was calculated if all fre-
quencies were equal to or greater than 5, otherwise a
Fisher’s Exact two-tailed test was used.(0–16 yrs) (0–16 yrs)
Cardiosurgery admissions 67.8% 57.8% 0.05
Cardiology admissions 13.2% 20.5% 0.06
Respiratory admissions 10.3% 13.5% 0.35
Other admissionsc 8.6% 8.1% 0.86
Antibiotic courses total 194 182 0.14
Prophylaxis courses 66.5% 55.5% 0.02*
Non-proven infection courses 27.3% 31.3% 0.39
Proven infection courses 6.2% 13.2% 0.02*
Secondary antibiotic courses total 8.2% 6% 0.59










Baseline demographics. *statistically significant, amean (min/median/max),
bmedian (min-max), cgeneral paediatric surgery, ENT, thoracic surgery.Results
Results of phase I (baseline period)
Assessing antibiotic use according to the CDC 12-step
campaign revealed 2 main areas in phase I for potential
improvement: i) Step 10: Empiric antibiotic therapy for
< 3 days for unproven infections (culture negative); ii)
Step 4: targeting of pathogens as therapy for proven
infections (culture positive). 18% (10/53) of empiric anti-
biotic courses had a duration of < 3 days and there was
no clear and reasonable documentation for courses of
longer durations. In 58% (7/12) a cultured pathogen was
targeted with a change of antibiotics unless antibiotics
were already susceptible. The other CDC steps showed
good results, i.e. 95% of all prophylactic courses com-
plied with institutional guidelines and vancomycin, car-
bapenems and third generation cephalosporins were
rarely used and did not appear in the top 5 most com-
monly used antibiotics (results not shown).Results of phase II (intervention period)
Baseline comparisons of patient demographics, overview
of antibiotic courses and outcomes are shown in Table 1.
There were significantly more proven infections during
phase II (24/182 against 12/194 during phase I; p=0.02),
but empiric antibiotic courses with negative culture
results were similar (Tab 1). After implementation of the
checklist in phase II, there was an increase in the
empiric antibiotic courses < 3 days from 18% (10/53)
during phase I to 35% (20/57; p=0.05). In additional a
further 40% (22/57) had clear and reasonable documen-
tation about reasons for continuing antibiotic therapy
despite negative culture results (clinical signs and/or
significantly raised infection markers). Therefore in
phase II, 74% (42/57) of empiric antibiotic courses were
classified as appropriate (p<0.0001). The percentage of
correctly targeted pathogens increased from 58% (7/12)
in phase I, to 83% (20/24) in phase II (p=0.21). The
checklist was used during phase II in 56 out of 81
courses of empiric or proven antibiotic therapies
(compliance rate of 69%).Regarding possible adverse outcomes due to early
discontinuation of antibiotic therapy there was no statisti-
cally significant difference in overall mortality, infection-
related mortality and infection relapse rate (Tab 1).
There was no case of death on our unit during the
phase I of the study, whereas 3 children died during
phase II, none of them infection related: i) cardiac
failure in a newborn baby with critical aortic stenosis,
ii) cardiac failure in a baby with unbalanced atrioven-
tricular septum defect and complete AV-block III
(palliative care), iii) ischemic necrotizing enterocolitis
after cardiopulmonary bypass surgery (antibiotic therapy
continued after surgery). Secondary courses of antibiotic
therapy during the same hospitalisation after a first
course of suspected or proven infection (possible
relapses of infection) were even less frequent in phase
II. The significantly higher rate of proven infections
in phase II was due to an increased rate of pulmonary
infections in the winter months November – February
compared to phase I in April – June.
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As with Patel et al. who evaluated antibiotic use
according to the CDC 12-step program on a NICU,
we used the CDC recommendations as the evaluation
tool for our audit [8,10]. Prolonged empiric anti-
microbial treatment without clear evidence of infec-
tion, failure to narrow antimicrobial therapy when a
causative organism is identified, and no clear docu-
mentation about indication and plan for therapy are
reported to be common problems, and published data
on general inappropriate use of antibiotics have similar
findings to our results during phase I [12-16].
The first step in building an intervention for antibiotic
surveillance/stewardship is to select the most appropriate
strategy that leads to a sustained improvement in a
defined area. In the guidelines for developing an institu-
tional program to enhance antimicrobial stewardship
there are two core strategies described: 1) prospective
audit with feedback and 2) formulary restriction and pre-
authorisation [4]. Initiation of antibiotic therapy in the
setting of a PICU patient is often empiric and based on
apparently worsening clinical condition, with sepsis as a
possible factor. During phase I of our audit vancomycin,
carbapenems and third generation cephalosporins were
not used regularly (not in our top 5 most commonly used
antibiotics) and we concluded that the local formulary
guidelines appeared to be respected without possible im-
provement with further formulary restriction and pre-
authorisation [16-18]. We therefore selected prospective
audit with feedback as a possible intervention, a strategy
proposed in a recent review by Newland as the most
favourable and efficient [11]. The basis on an audit and
feedback intervention is a review of every antibiotic course
by a third party (typically an infectious disease physician
or a clinical pharmacist) with the audit presented back to
the prescriber. For implementation we faced the same bar-
riers reported in other paediatric antibiotic stewardship
programs: lack of resources, including funding, time, and
personnel [9,11]. We solved this challenge by developing a
new strategy for audit and feedback. Instead of personnel
audit and feedback by a third party, we created a checklist
and used this as a way of audit and feedback (checklist as
mandatory form for self-review and feedback by the treat-
ing physician). Recent publications about successful use of
simple checklists guided us in developing our intervention
[19-21]. Key elements for creating a successful checklist
are short, clear and basic questions with reminders of rou-
tine care [19]. With our checklist, we aimed to support
the communication and documentation of indications for
the initiation and continuation of antibiotic therapy, which
served to remind the treating physician to review and po-
tentially stop therapy or target the isolated pathogen.
There are other publications regarding the use of
mandatory prescription forms to start antibiotic therapy[22]. The innovation of our approach is that the
clinician is reviewing the prescription with help of a
checklist at 2 points after start of antibiotic therapy
(at 48 hours and 5 days).
The importance of a high compliance rate (power cal-
culation aimed for a compliance rate of 80%) for a suc-
cessful intervention is emphasised with the statistically
not significant increase of antibiotic courses of empiric
therapy < 3 days. In contrast to the aviation industry,
there is still scepticism by some physicians about the use
of checklists for the safe routine care and emergency
situations in medicine, illustrated with a citation from A.
Gawande in his recently published book “The Checklist
Manifesto”: “It runs counter to deeply held beliefs about
how the truly great among us – those we aspire to be –
handle situations of high stakes and complexity” [19]. A
mandatory checklist in a computerised prescription sys-
tem offers a possible way to improve compliance and
impact of the intervention. Due to the potential risk of
premature discontinuation of therapy a computerised
checklist has to be mandatory but without an automatic
antibiotic stop-order [23].
The limitations of our audit were the short surveil-
lance time, the low compliance to the intervention
(<80%) and the low numbers of proven infection with
positive cultures (no conclusions regarding susceptibility
patterns possible). The main strength of our audit was
that it was a simple and achievable intervention which
was low in cost (no additional funding) and resources.
The construction of an easy attainable strategy is very
important due to the fact that lack of resources and time
are major barriers to implementing an antimicrobial
stewardship program in paediatrics.
Conclusions
The 12 steps of the CDC campaign are a possible tool to
evaluate institutional antibiotic therapy. A mandatory
checklist as an audit-feedback-mechanism can be a simple
achievable intervention with possible improvement in
antibiotic use at minimal expense. Further studies with
mandatory, computerised checklists within the prescribing
system need to be carried out to show compliance and
sustainable results over a longer period of time.
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